Notable Reporting: Could Opko Health Inc. See a Reversal After This Very Strong Session?

Notable Reporting: Could Opko Health Inc. See a Reversal After This Very Strong Session?

The stock of Opko Health Inc. (NASDAQ:OPK) is a huge mover today! The stock increased 4.90% or $0.5 on November 23, hitting $10.7. About 4.06M shares traded hands or 20.47% up from the average. Opko Health Inc. (NASDAQ:OPK) has declined 4.89% since April 22, 2016 and is downtrending. It has underperformed by 10.30% the S&P500.
The move comes after 7 months positive chart setup for the $5.83 billion company. It was reported on Nov, 24 by Barchart.com. We have $11.02 PT which if reached, will make NASDAQ:OPK worth $174.90M more.

Analysts await Opko Health Inc. (NASDAQ:OPK) to report earnings on March, 6. After $-0.03 actual earnings per share reported by Opko Health Inc. for the previous quarter, Wall Street now forecasts 66.67% negative EPS growth.

According to Zacks Investment Research, “OPKO Health is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies.”

Insitutional Activity: The institutional sentiment increased to 1.8 in Q2 2016. Its up 0.80, from 1 in 2016Q1. The ratio increased, as 33 funds sold all Opko Health Inc. shares owned while 63 reduced positions. 22 funds bought stakes while 74 increased positions. They now own 102.34 million shares or 2.14% more from 100.19 million shares in 2016Q1.
Fairfield Bush & owns 102,478 shares or 0.33% of their US portfolio. Profund Ltd Liability Co reported 173,454 shares or 0.08% of all its holdings. Jaffetilchin Prns Ltd Limited Liability Company holds 450,450 shares or 1.28% of its portfolio. Commonwealth Equity Svcs has 0.01% invested in the company for 66,958 shares. Lba Wealth Mgmt Limited Company last reported 500 shares in the company. Rfg Advisory Group Limited Company owns 10,052 shares or 0.08% of their US portfolio. Clal Enter Hldgs Ltd last reported 0.54% of its portfolio in the stock. The Iowa-based Cambridge Investment Advsr has invested 0.12% in Opko Health Inc. (NASDAQ:OPK). The Pennsylvania-based Cordasco Network has invested 0.01% in Opko Health Inc. (NASDAQ:OPK). First Advsrs Limited Partnership accumulated 1.53 million shares or 0.04% of the stock. Commerzbank Aktiengesellschaft Fi holds 28,190 shares or 0% of its portfolio. Raymond James Service Advsrs, a Florida-based fund reported 38,137 shares. Art Advisors Ltd Llc, a New York-based fund reported 87,443 shares. Aperio Gp Limited Liability reported 57,248 shares or 0% of all its holdings. Envestnet Asset Management owns 11,356 shares or 0% of their US portfolio.

Insider Transactions: Since May 26, 2016, the stock had 64 buys, and 0 insider sales for $5.67 million net activity. $92,800 worth of shares were bought by FROST PHILLIP MD ET AL on Friday, September 2.

OPK Company Profile

OPKO Health, Inc. (OPKO), incorporated on November 18, 1991, is a healthcare company. The Firm operates through two divisions: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical activities in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations. The Company’s diagnostics business includes Bio-Reference Laboratories (Bio-Reference), which is a clinical laboratory with a genetic testing business, including the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The Company’s pharmaceutical business features Rayaldee, a treatment for secondary hyperparathyroidism (SHPT) in patients with stage III or IV chronic kidney disease (CKD) and vitamin D insufficiency and VARUBI for chemotherapy-induced nausea and vomiting. The Company’s pharmaceutical business includes OPKO Biologics, which features hGH-CTP, a once-weekly human growth hormone injection (in Phase III and partnered with Pfizer), and a longer acting Factor VIIa drug for hemophilia (Phase IIa). In addition to its pharmaceutical and diagnostic development programs, it owns pharmaceutical platforms in Ireland, Chile, Spain and Mexico. The Firm has a development and commercial supply pharmaceutical company, as well as a global supply chain operation and holding firm in Ireland. It also owns a specialty active pharmaceutical ingredients (APIs) maker in Israel.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment